MedTrace Logo

Neoadjuvant Endocrine Therapy in Breast Cancer. Real Clinical Practice in Russia

NCT05800197 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2023-04-06

No results posted yet for this study

Summary

Neoadjuvant Endocrine Therapy for pre- and postmenopausal women with T4 Nany or TanyN2-3 estrogen receptor (ER) -positive, progrsteron receptor (PR) -positive and HER2 negative breast cancer. Real Clinical Practice in Russia.

Conditions

Interventions

DRUG

Tamoxifen 20mg

Selective estrogen receptor modulator

DRUG

Anastrozole 1mg

Aromatase Inhibitor

DRUG

Letrozole 2.5mg

Aromatase Inhibitor

DRUG

Goserelin

Gonadotropin Releasing Hormone (GnRH) agonist

DRUG

Triptorelin

Gonadotropin Releasing Hormone (GnRH) agonist

Sponsors & Collaborators

  • Blokhin's Russian Cancer Research Center

    lead OTHER

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-15
Primary Completion
2023-08-15
Completion
2025-01-15

Countries

  • Russia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05800197 on ClinicalTrials.gov